FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224305911> ?p ?o ?g. }

• W4224305911 endingPage "3592" @default.
• W4224305911 startingPage "3581" @default.
• W4224305911 abstract "Kirsten rat sarcoma viral oncogene homolog (KRAS) is an important driver gene of non-small cell lung cancer (NSCLC). Despite a rapid progress achieved in the targeted therapy, chemotherapy remains the standard treatment option for patients with KRAS-mutant NSCLC. This study aimed to assess real-world data of Chinese patients with KRAS-mutant NSCLC undergoing chemotherapy and/or immunotherapy.KRAS mutational status was analyzed using next-generation sequencing of 150,327 NSCLC patients from the Lung Cancer Big Data Precise Treatment Collaboration Group (LANDSCAPE) project (Cohort I). Treatment data were collected and analyzed retrospectively from 4348 NSCLC patients who were admitted to the Peking University Cancer Hospital and Institute between January 2009 and October 2020 (Cohort II).In Cohort I, 18,224 patients were detected with KRAS mutations (12.1%) of whom G12C (29.6%) was the most frequent subtype, followed by G12D (18.1%) and G12V (17.5%). In case of concomitant mutations, TP53 had the highest incidence of 33.6%, followed by EGFR (11.6%), STK11 (10.4%), KEAP1(6.2%), and CDKN2A (6.0%). Cohort II included 497 patients (11.4%) with KRAS mutations. In the first-line chemotherapeutic analysis of Cohort II, patients benefited more from the pemetrexed/platinum (PP) regimen than the gemcitabine/platinum (GP) or taxanes/platinum (TP) regimen (median progression-free survival [PFS], 6.4 vs. 4.9 vs. 5.6 months, hazard ratio [HR] = 0.65, 95% confidence interval [CI] 0.48-0.88, p = 0.033 and HR = 0.69, 95% CI 0.47-1.00, p = 0.05, respectively), with no significant difference when combined with bevacizumab. Regarding patients who received immune checkpoint inhibitors (ICIs), the objective response rate was 26% for a median PFS of 9.6 months (95% CI 6.16-13.03). Patients who received ICIs combined with chemotherapy had a significantly longer survival than monotherapy (median PFS, 13.9 vs. 5.2 months, HR = 0.59, 95% CI 0.35-0.99, p = 0.049).KRAS is an important driver gene in NSCLC, compromising 12.1% in this study, and G12C was noted as the most common subtype. Patients with KRAS-mutant NSCLC could benefit from pemetrexed-based chemotherapy and ICIs." @default.
• W4224305911 created "2022-04-26" @default.
• W4224305911 creator A5002059103 @default.
• W4224305911 creator A5006210028 @default.
• W4224305911 creator A5006578917 @default.
• W4224305911 creator A5019910092 @default.
• W4224305911 creator A5021078253 @default.
• W4224305911 creator A5022222545 @default.
• W4224305911 creator A5022356244 @default.
• W4224305911 creator A5028062402 @default.
• W4224305911 creator A5037799837 @default.
• W4224305911 creator A5037954928 @default.
• W4224305911 creator A5040213887 @default.
• W4224305911 creator A5040296857 @default.
• W4224305911 creator A5060831159 @default.
• W4224305911 creator A5067221645 @default.
• W4224305911 creator A5085280649 @default.
• W4224305911 date "2022-04-08" @default.
• W4224305911 modified "2023-09-30" @default.
• W4224305911 title "The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐Mutant Non‐Small Cell lung cancer" @default.
• W4224305911 cites W2029908992 @default.
• W4224305911 cites W2054001332 @default.
• W4224305911 cites W2056912918 @default.
• W4224305911 cites W2086077373 @default.
• W4224305911 cites W2104347254 @default.
• W4224305911 cites W2104830962 @default.
• W4224305911 cites W2143814205 @default.
• W4224305911 cites W2166923287 @default.
• W4224305911 cites W2181288074 @default.
• W4224305911 cites W2252486508 @default.
• W4224305911 cites W2277124765 @default.
• W4224305911 cites W2323356988 @default.
• W4224305911 cites W2405831219 @default.
• W4224305911 cites W2527905628 @default.
• W4224305911 cites W2547499110 @default.
• W4224305911 cites W2561459036 @default.
• W4224305911 cites W2567564314 @default.
• W4224305911 cites W2572174216 @default.
• W4224305911 cites W2608102145 @default.
• W4224305911 cites W2613467753 @default.
• W4224305911 cites W2756918081 @default.
• W4224305911 cites W2767162493 @default.
• W4224305911 cites W2770828094 @default.
• W4224305911 cites W2777461561 @default.
• W4224305911 cites W2796582438 @default.
• W4224305911 cites W2804050059 @default.
• W4224305911 cites W2804812017 @default.
• W4224305911 cites W2883160489 @default.
• W4224305911 cites W2888630309 @default.
• W4224305911 cites W2898735291 @default.
• W4224305911 cites W2913235593 @default.
• W4224305911 cites W2947987576 @default.
• W4224305911 cites W2981114563 @default.
• W4224305911 cites W2981596557 @default.
• W4224305911 cites W2982602983 @default.
• W4224305911 cites W2983359513 @default.
• W4224305911 cites W2998386687 @default.
• W4224305911 cites W3037204750 @default.
• W4224305911 cites W3172081492 @default.
• W4224305911 cites W3203110794 @default.
• W4224305911 cites W4224305911 @default.
• W4224305911 doi "https://doi.org/10.1002/cam4.4739" @default.
• W4224305911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35394121" @default.
• W4224305911 hasPublicationYear "2022" @default.
• W4224305911 type Work @default.
• W4224305911 citedByCount "8" @default.
• W4224305911 countsByYear W42243059112022 @default.
• W4224305911 countsByYear W42243059112023 @default.
• W4224305911 crossrefType "journal-article" @default.
• W4224305911 hasAuthorship W4224305911A5002059103 @default.
• W4224305911 hasAuthorship W4224305911A5006210028 @default.
• W4224305911 hasAuthorship W4224305911A5006578917 @default.
• W4224305911 hasAuthorship W4224305911A5019910092 @default.
• W4224305911 hasAuthorship W4224305911A5021078253 @default.
• W4224305911 hasAuthorship W4224305911A5022222545 @default.
• W4224305911 hasAuthorship W4224305911A5022356244 @default.
• W4224305911 hasAuthorship W4224305911A5028062402 @default.
• W4224305911 hasAuthorship W4224305911A5037799837 @default.
• W4224305911 hasAuthorship W4224305911A5037954928 @default.
• W4224305911 hasAuthorship W4224305911A5040213887 @default.
• W4224305911 hasAuthorship W4224305911A5040296857 @default.
• W4224305911 hasAuthorship W4224305911A5060831159 @default.
• W4224305911 hasAuthorship W4224305911A5067221645 @default.
• W4224305911 hasAuthorship W4224305911A5085280649 @default.
• W4224305911 hasBestOaLocation W42243059112 @default.
• W4224305911 hasConcept C121608353 @default.
• W4224305911 hasConcept C126322002 @default.
• W4224305911 hasConcept C143998085 @default.
• W4224305911 hasConcept C207103383 @default.
• W4224305911 hasConcept C2776256026 @default.
• W4224305911 hasConcept C2780258809 @default.
• W4224305911 hasConcept C2781187634 @default.
• W4224305911 hasConcept C2781413609 @default.
• W4224305911 hasConcept C44249647 @default.
• W4224305911 hasConcept C526805850 @default.
• W4224305911 hasConcept C71924100 @default.
• W4224305911 hasConcept C72563966 @default.
• W4224305911 hasConcept C88879693 @default.

• next